MyBlueDots

Radiation plus combination immunotherapy may help preserve bladder in some patients with cancer

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses that allowed for bladder preservation, according to results from the IMMUNOPRESERVE clinical trial published in Clinical Cancer Research.
Read More

Novel antibody discovery platform may inform Alzheimer’s and Parkinson’s research

In diseases like Parkinson’s and Alzheimer’s, specific proteins misfold and clump together, forming toxic aggregates that damage brain cells. The process of proteins spontaneously clumping is called protein aggregation and researchers have developed novel methods to generate aggregate-specific antibodies as specific probes or modulators of the aggregation process.
Read More

Robert F. Kennedy Jr. says antidepressants are harder to quit than heroin—is he right?

Robert F. Kennedy Jr. has been sworn in as the US health and human services secretary, despite saying a few things that raised eyebrows during his confirmation hearing. One of those things was the claim that some people have a harder time coming off antidepressants than they do coming off heroin. He was referring specifically to the current generation of antidepressants called selective serotonin reuptake inhibitors, or SSRIs.
Read More

Accelerated drug-testing platform for ALS paves way for therapeutic innovation

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) has been working with national and international stakeholders to accelerate ALS research by launching the first platform trial in ALS to simultaneously test multiple drugs using shared trial infrastructure and placebo data.
Read More
Top